SUBSCRIBE
SUBSCRIBE
News   Drug Development

Almirall Begins Aclidinium Tests to Get FDA Okay

April 30, 2009 | 
1 min read

MADRID, April 30 (Reuters) - Spanish drug maker Almirall (ALM.MC) said on Thursday it had begun a programme to comply with U.S. and EU authorities’ recommendations regarding phase III trials of lung drug aclidinium bromide.

Clinical research Phase III Europe
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Courtesy of Sarepta Therapeutics
Earnings
Sarepta Halts Development of Next-Gen DMD Drug, Reports Robust Elevidys Sales
November 7, 2024
 · 
2 min read
 · 
Heather McKenzie
3D illustration of a T cell killing a cancer cell
CAR-T
Gilead, Arcellx Tout Best-in-Class Potential for CAR T Therapy in Multiple Myeloma
November 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: A collage representing cell and gene the
Gene editing
Patient Death Taints Otherwise Positive Data for Beam’s Sickle Cell Gene Therapy
November 5, 2024
 · 
3 min read
 · 
Annalee Armstrong
Pictured: AstraZeneca's manufacturing facility in
Obesity
AstraZeneca Bolsters Obesity Pipeline With Promising Early Data for Candidates
November 5, 2024
 · 
3 min read
 · 
Tristan Manalac